Avenue Therapeutics, INC 8-K filings

Avenue Therapeutics secured an exclusive worldwide license from Duke University for ATX-04 to treat Pompe disease, leveraging existing clinical data.

Avenue Therapeutics, Inc. announced that its stockholders approved the election of six directors and ratified KPMG LLP as its independent auditor for 2025 at the annual meeting.

Avenue Therapeutics, Inc. has announced December 30, 2025, as the date for its annual meeting of stockholders and established deadlines for shareholder proposals and director nominations.

Avenue Therapeutics divests its majority-owned subsidiary Baergic Bio to Axsome Therapeutics, securing an upfront payment and potential future milestone and royalty payments for its epilepsy drug candidate.

Avenue Therapeutics and AnnJi Pharmaceutical have terminated their license agreement, with Avenue transferring rights to AJ201 back to AnnJi and receiving potential milestone payments and royalties.

Avenue Therapeutics, Inc. has been notified by Nasdaq that its common stock will be delisted due to non-compliance with minimum stockholders' equity requirements.

Avenue Therapeutics is navigating Nasdaq compliance issues and a dispute over a key license agreement, casting uncertainty over its future.

Avenue Therapeutics has received a delisting notice from Nasdaq due to not meeting the minimum stockholders' equity requirement, despite believing they have since regained compliance.

Avenue Therapeutics reported its third quarter 2024 financial results and provided an update on its clinical programs, including the anticipated topline data for AJ201.

Avenue Therapeutics has granted restricted stock units to its CEO and Interim Principal Financial Officer, vesting over a period of two years.

Avenue Therapeutics reported its second quarter 2024 financial results, highlighted by the completion of a Phase 1b/2a trial for AJ201 and a $4.4 million capital raise.

Avenue Therapeutics stockholders approved an amendment to the 2015 Incentive Plan, increasing share availability and extending the plan's term, and elected six directors at their annual meeting on June 24, 2024.

Avenue Therapeutics has received formal notice from Nasdaq that it has regained compliance with listing requirements, specifically the minimum stockholders' equity rule.

Avenue Therapeutics announced its first quarter 2024 financial results, highlighting progress in its clinical programs and a recent capital raise.

Avenue Therapeutics has entered into an agreement to sell up to $3.85 million of its common stock through an at-the-market offering.

Avenue Therapeutics has successfully raised approximately $4.4 million by inducing warrant holders to exercise their existing warrants at a reduced price.

Avenue Therapeutics has enacted a 1-for-75 reverse stock split to meet Nasdaq's minimum bid price requirement, effective April 26, 2024.

Avenue Therapeutics received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement, but has been granted an extension to regain compliance.

Avenue Therapeutics reported its 2023 financial results and highlighted progress in its clinical programs, including the completion of enrollment for the AJ201 trial and advancements in BAER-101 and IV tramadol development.

Avenue Therapeutics has received an extension from Nasdaq until May 20, 2024, to meet minimum stock price and equity requirements for continued listing.

Avenue Therapeutics has obtained shareholder consent to enact a reverse stock split within a 30-for-1 to 75-for-1 range, with the exact ratio to be determined by the board.

Avenue Therapeutics has increased its authorized common stock shares from 75 million to 200 million following stockholder approval.

Avenue Therapeutics has received majority shareholder consent to increase its authorized common stock and approve the issuance of shares related to previously disclosed warrants.